Long-term statin use and the risk of gallstone disease: A population-based case-control study

American Journal of Epidemiology

Volumn 173, Issue 2, 2011, Pages 162-170

  Erichsen, Rune ^a   Frøslev, Trine ^a   Lash, Timothy L ^a,b   Pedersen, Lars ^a   Sørensen, Henrik Toft ^a,b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

cholelithiasis; gallstones; hydroxymethylglutaryl CoA reductase inhibitors; risk

Indexed keywords

ANTILIPEMIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

DISEASE PREVALENCE; DRUG; HABITAT TYPE; INHIBITION; INHIBITOR; LIPID; LOGISTICS; REGRESSION ANALYSIS; RISK FACTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CHOLELITHIASIS; CONTROLLED STUDY; DENMARK; DISEASE ASSOCIATION; DRUG EXPOSURE; DRUG USE; FEMALE; HUMAN; INFANT; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; PRESCHOOL CHILD; PRESCRIPTION; SCHOOL CHILD;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; DENMARK; FEMALE; GALLSTONES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; ODDS RATIO;

DENMARK;

EID: 78650644688     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwq361     Document Type: Article

References (33)

1. Kratzer W, Mason RA, Kächele V. Prevalence of gallstones in sonographic surveys worldwide. J Clin Ultrasound. 1999; 27(1):1-7.
2. Katsika D, Grjibovski A, Einarsson C, et al. Genetic and environmental influences on symptomatic gallstone disease: a Swedish study of 43,141 twin pairs. Hepatology. 2005; 41(5):1138-1143.
3. Portincasa P, Moschetta A, Petruzzelli M, et al. Gallstone disease: symptoms and diagnosis of gallbladder stones. Best Pract Res Clin Gastroenterol. 2006;20(6):1017-1029.
4. Portincasa P, Moschetta A, Palasciano G. Cholesterol gallstone disease. Lancet. 2006;368(9531):230-239.
5. Caroli-Bosc FX, Le Gall P, Pugliese P, et al. Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: epidemiological study in an unselected population. Dig Dis Sci. 2001;46(3):540-544.
6. Tsai CJ, Leitzmann MF, Willett WC, et al. Statin use and the risk of cholecystectomy in women. Gastroenterology. 2009; 136(5):1593-1600.
7. Bodmer M, Brauchli YB, Krähenbühl S, et al. Statin use and risk of gallstone disease followed by cholecystectomy. JAMA. 2009;302(18):2001-2007.
8. Merzon E, Weiss NS, Lustman AJ, et al. Statin administration and risk of cholecystectomy: a population-based case-control study. Expert Opin Drug Saf. 2010;9(4):539-543.
9. Walley T, Mantgani A. The UK General Practice Research Database. Lancet. 1997;350(9084):1097-1099.
10. Fujita T. Use of statins and gallstone risk. JAMA. 2010; 303(12):1146-1147.
11. Hsu CS, Kao JH. Use of statins and gallstone risk [letter]. JAMA. 2010;303(12):1146.
12. StatBank Denmark. Population and Elections. Table FOLK1. Copenhagen, Denmark: Statistics Denmark; 2010. (http:// www.statistikbanken.dk/statbank5a/ default.asp?w1613). (Accessed on November 1, 2010).
13. Frank L. Epidemiology. When an entire country is a cohort. Science. 2000;287(5462):2398-2399.
14. Andersen TF, Madsen M, Jørgensen J, et al. The Danish National Hospital Register. A valuable source of data for modern health sciences [in Danish]. Dan Med Bull. 1999;46(3):263-268.
15. Nielsen G, Sørensen H, Zhou W, et al. The pharmacoepide-miologic prescription database of North Jutland-a valid tool in pharmacoepidemiological research. Int J Risk Safety Med. 1997;10(3):203-205.
16. Gaist D, Sørensen HT, Hallas J. The Danish prescription registries [in Danish]. Dan Med Bull. 1997;44(4):445-448.
17. Kratzer W, Haenle MM, Mason RA, et al. Prevalence of cholelithiasis in patients with chronic inflammatory bowel disease. World J Gastroenterol. 2005;11(39):6170-6175.
18. Attili AF, Capocaccia R, Carulli N, et al. Factors associated with gallstone disease in the MICOL experience. Multicenter Italian Study on Epidemiology of Cholelithiasis. Hepatology. 1997;26(4):809-818.
19. Méndez-Sánchez N, Bahena-Aponte J, Chávez-Tapia NC, et al. Strong association between gallstones and cardiovascular disease. Am J Gastroenterol. 2005;100(4):827-830.
20. Yoo EH, Lee SY. The prevalence and risk factors for gallstone disease. Clin Chem Lab Med. 2009;47(7):795-807.
21. Rothman KJ, Greenland S, Lash TL, eds. Modern Epidemiology. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008.
22. Smith JL, Roach PD, Wittenberg LN, et al. Effects of sim-vastatin on hepatic cholesterol metabolism, bile lithogenicity and bile acid hydrophobicity in patients with gallstones. J Gastroenterol Hepatol. 2000;15(8):871-879.
23. Reihnér E, Rudling M, Staihlberg D, et al. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. N Engl J Med. 1990; 323(4):224-228.
24. Duane WC, Hunninghake DB, Freeman ML, et al. Simvasta-tin, a competitive inhibitor of HMG-CoA reductase, lowers cholesterol saturation index of gallbladder bile. Hepatology. 1988;8(5):1147-1150.
25. Smit JW, van Erpecum KJ, Renooij W, et al. The effects of the 3-hydroxy, 3-methylglutaryl coenzyme A reductase inhibitor pravastatin on bile composition and nucleation of cholesterol crystals in cholesterol gallstone disease. Hepatology. 1995; 21(6):1523-1529.
26. Tazuma S, Ohya T, Mizuno T, et al. Effects of fluvastatin on human biliary lipids. Am J Cardiol. 1995;76(2):110A- 113A.
27. Davis KG, Wertin TM, Schriver JP. The use of simvastatin for the prevention of gallstones in the lithogenic prairie dog model. Obes Surg. 2003;13(6):865-868.
28. Abedin MZ, Narins SC, Park EH, et al. Lovastatin alters biliary lipid composition and dissolves gallstones: a long-term study in prairie dogs. Dig Dis Sci. 2002;47(10):2192-2210.
29. Mosbech J, Jørgensen J, Madsen M, et al. The national patient registry. Evaluation of data quality [in Danish]. Ugeskr Laeger. 1995;157(26):3741-3745.
30. Thomsen RW, Thomsen HF, Nørgaard M, et al. Risk of cholecystitis in patients with cancer: a population-based cohort study in Denmark. Cancer. 2008;113(12):3410-3419.
31. Thomsen RW, Johnsen SP, Olesen AV, et al. Socioeconomic gradient in use of statins among Danish patients: population-based cross-sectional study. Br J Clin Pharmacol. 2005; 60(5):534-542.
32. Bodmer M, Brauchli YB, Meier CR. Use of statins and gallstone risk-reply [letter]. JAMA. 2010;303(12):1147.
33. Erichsen R, Frøslev T, Pedersen L, et al. Long-term statin use reduces the risk of gallstone disease: a population-based case-control study [abstract]. Pharmacoepidemiol Drug Safe. 2010;19(suppl 1):138.